Back to search results

Stereotactic Radiosurgery for Cancer-Related Pain

This study is looking at whether a treatment called hypophysectomy (treating the pituitary gland) using stereotactic radiosurgery (SRS), a type of focused radiation, can help people with cancer-related pain that is difficult to control. Researchers want to see if this treatment is safe and if it can reduce pain, improve mood, and potentially decrease the need for opioid medications. You might be able to join if you are at least 18 years old, can speak English, have a confirmed cancer diagnosis, and experience poorly controlled pain that affects your daily life. The study aims to enroll 40 participants to understand if this approach is feasible for future, larger studies.

Study design
This is an interventional study planning to enroll 40 participants. It is designed to evaluate the safety and feasibility of the treatment.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your safety and any side effects will be monitored throughout the study, which is expected to be an average of one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06287515

Hypophysectomy by Stereotactic Radiosurgery for Cancer-Related Pain

Recruiting
PHASE1Ages 18+InterventionalSupportive care
M.D. Anderson Cancer Center
~40 participants
Updated 2026-07-16 on ClinicalTrials.gov
What's tested:Stereotactic Radiosurgery

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and adverse events (AEs)
Measured over Through study completion; an average of 1 year

Conditions

Hypophysectomy

Explore related trials

Malignant Neoplasm

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Chenyang Wang, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Chenyang Wang, MD
[email protected]
(832) 710-1570
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years old on the day of signing informed consent and willing and able to sign a written informed consent.
English fluency in order to complete PROs and neurocognitive assessment
Pathologic or cytologic confirmation of malignancy.
Poorly controlled intractable nociceptive or mixed pain limiting function or quality of life. Participants must have exhausted or not a candidate for standard of care pain control measures such as opioids, injections/ablations, conventional radiation therapy, or surgical intervention with a curative intent and pain limiting function that affects the participants quality of life in the judgment of the treating physician. Refractory status will require at least consultation and two follow-up visits with pain specialists (pain management or supportive care).
ECOG performance status of 0-3.
Life expectancy is greater than 4 weeks and less than 1 year in the treating physician's judgment.

Exclusion

Participants with prior cranial or head/neck radiation where cumulative organ-at-risk dose constraints cannot be achieved (see section 4.2).
Inability to have an MRI of the brain for reasons such as a non-compatible bioimplant that could be displaced during MRI, shrapnel embedded (such as from war wounds), metal workers, and machinists (potential for metallic fragments in or near the eyes).
Expressions of pain due to depression, delirium or addictive behavior
Participants who are pregnant.
Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study in the judgment of the Investigators.

What this trial measures

  • Safety and adverse events (AEs)Through study completion; an average of 1 year

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0